JYJun Yang

Jun Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun Yang has a total of 247 co-authors. Here are the top co-authors by number of shared publications:

  • Tingyan He

    Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China; University of Pittsburgh, Departments of Medicine and Immunology, Division of Rheumatology, Pittsburgh, PA, USA

    7 shared publications
  • Yanyan Huang

    Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China

    7 shared publications
  • Yu Xia

    Department of Rheumatology and Immunology, Shenzhen Children’s hospital, Shenzhen, China

    7 shared publications
  • Tingyan He

    Department of Rheumatology and Immunology, Shenzhen Children’s hospital, Shenzhen, China

    6 shared publications
  • Linlin Wang

    Department of Rheumatology and Immunology, Shenzhen Children’s Hospital

    5 shared publications
  • Ying Luo

    Department of Rheumatology and Immunology, Shenzhen Children’s hospital, Shenzhen, China

    5 shared publications

Latest Publications

  • Multicenter international cohort study of haploinsufficiency of A20 reveals novel genetic architecture and phenotypic evolution

    by Tingyan He, Jun Wang, Manuel Carpio Tumba, Shihao Wang, Youyou Luo, Jie Chen, Guomin Li, Zhou Shu, Song Zhang, Deborah L. Stone, et al.


  • Open Access

    CyTOF analysis of immune characteristics in cSLE: belimumab treatment and refractory cases

    by Ying Luo, Linlin Wang, Yongbin Xu, Qian Chen, Ki Pui Lam, Xiaona Zhu, Qiru Su, Shuli Luo, Jun Yang

    Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. Some patients still develop severe refractory SLE despite conventional treatments. Belimumab, a biologic targeting B lymphocyte stimulator (BLyS), shows therapeutic promise in SLE, but its effects on pediatric patients remain unclear. Methods: This study used CyTOF to analyze immunophenotypic changes before and after belimumab treatment and investigate immune features in refractory SLE. Results: Results showed that belimumab treatment primarily reduced transitional and naïve B cells, and also decreased age-associated B cells (ABCs), a subset implicated in autoimmunity or chronic inflammation. Plasma cells and plasmablasts persisted in refractory cases. CD38 expression on B cells was elevated in severe disease and correlated with disease activity, while CD73 expression increased during recovery and inversely correlated with activity. Discussion: These findings indicate that combining belimumab with conventional therapy induces significant immune modulation, particularly within B cells. Persistent plasma cells and plasmablasts may contribute to disease refractoriness. CD38 and the CD73-mediated adenosine pathway may provide insights for future research strategies in SLE.

  • Open Access

    Multicenter international cohort study of HA20 reveals novel genetic architecture and phenotypic evolution

    by Tingyan He, Jun Wang, Manuel Carpio Tumba, Shihao Wang, Youyou Luo, Jie Chen, Guomin Li, Zhou Shu, Song Zhang, Deborah L Stone, et al.

    Background: Haploinsufficiency of A20 (HA20) is an immune dysregulation disorder caused by loss-of-function TNFAIP3 mutations. This international multicenter study aimed to delineate its clinical spectrum, genetic basis, and natural history. Methods: A cross-sectional, retrospective analysis was conducted in HA20 patients with pathogenic or likely pathogenic TNFAIP3 variants. Clinical, laboratory and treatment data were assessed. Clustering analysis was applied to evaluate clinical features and disease phenotypes. Patients were stratified by age (< 16 years vs ≥ 16 years), country of origin (China vs U.S.), and gender. Results: A total of 185 patients from 41 clinics across 7 countries were included (median onset 3.3 years). Common clinical features were mucocutaneous involvement (80.5%), recurrent fever (63.3%), gastrointestinal symptoms (58.6%), cytopenias (56.6%), arthritis/arthralgia (46.7%), and recurrent infections (35.5%). Compared with adults and patients from the U.S. cohort, intestinal ulcers were significantly more frequent in children and patients from the Chinese cohort ( P = 0.002 and P < 0.0001, respectively), whereas uveitis was less common in these groups ( P = 0.001 and P < 0.0001, respectively). Hierarchical clustering of clinical disease phenotypes based on Pearson distance identified two major clusters, an autoinflammation-predominant phenotype and an autoimmune-predominant phenotype. The autoinflammation-predominant phenotype was more common in children and patients from the Chinese cohort ( P = 0.033 and P = 0.003, respectively). A total of 89 pathogenic TNFAIP3 mutations were identified, including 46 novel variants. Large deletions were associated with neurologic disease and developmental delay ( P = 0.0054 and P = 0.0245, respectively); however, there were no clear association between disruptions of specific functional A20 domains and onset age or phenotype. Therapeutically, TNF and IL-1 inhibitors were effective in most patients, with thalidomide and JAK inhibitors used in refractory cases; 51.5% had achieved minimal disease activity at the most recent follow-up. Conclusions: HA20 is a common dominantly inherited immune dysregulation disorder with phenotypic heterogeneity and potential age-dependent evolution. This large international cohort highlights diagnostic and therapeutic strategies to advance evaluation and management of HA20.


  • Open Access

    The clinical features and outcome of Kawasaki disease combined with G6PD deficiency

    by Peisi Cheng, Tingyan He, Jun Yang

    The characteristics and prognosis of Kawasaki disease (KD) patients with glucose-6-phosphate dehydrogenase deficiency (G6PDd) remain unknown. This study pr

  • Open Access

    Case Report: Novel UNC93B1 variant causes rheumatoid arthritis and interstitial pneumonia

    by Tingyan He, Junbin Ou, Lijuan Huang, Xinyi Zhou, Linlin Wang, Xiaolin Li, Jun Yang

    Background: UNC93B1 is a transmembrane protein essential for regulating toll-like receptors (TLRs). Pathogenic variants in human UNC93B1 have recently been described in a limited number of patients with childhood systemic lupus erythematosus and chilblain lupus.Methods: Demographic data, medical history, and physical examination findings were obtained. Whole-exome sequencing and Sanger sequencing were performed. The interferon-stimulated gene (ISG) score was analyzed.Results: We report four patients with a novel UNC93B1 c.1007G>A p.R336H variant, including three presenting with juvenile arthritis or rheumatoid arthritis, and one with a predominant phenotype of ITP. In addition to arthritis, these patients presented with interstitial pneumonia as the dominant feature. ISG expression analysis during active disease revealed overexpression of IFN-stimulated cytokine genes and an elevated ISG score in P4. To date, 25 cases with UNC93B1 pathogenic mutations have been reported, including 13 with childhood-onset systemic lupus erythematosus (SLE) and 12 with cutaneous lupus. Management of these patients has varied based on clinical manifestations.Conclusion: UNC93B1-mutation-associated disease should be considered in the context of early-onset autoimmune disease, especially childhood-onset SLE, juvenile arthritis, and rheumatoid arthritis. Pulmonary involvement should also be monitored in these patients.


  • Open Access

    Clinical characteristics and outcomes of COVID-19 in pediatric patients with rheumatic diseases

    by Yating Wang, Shu Su, Mingsheng Ma, Ruohang Weng, Zhiyong Zhang, Dawei Liu, Xin Yan, Junjun Wang, Yajun Wang, Wei Zhang, et al.

    Background: This study investigates the clinical characteristics and outcomes of pediatric patients with rheumatic diseases infected with COVID-19 in China. Methods: We conducted a retrospective analysis of pediatric patients with rheumatic diseases who contracted COVID-19. Data were collected via a comprehensive questionnaire with a 14-day follow-up. Multivariable logistic regression was used to assess severe outcomes, and network analyses evaluated symptom correlations. Results: A total of 1070 cases were collected. Fever (88.05%) and cough (62.75%) were the most common symptoms. Cough, nasal congestion, and runny nose exhibited a stronger correlation with each other. A higher incidence of fever reduced the incidence of two single symptoms (nasal congestion [r = −0.833], runny nose [r = −0.762]). Vaccinated children showed a shorter time to negative COVID-19 conversion (7.21 days vs. 7.63 days, p < 0.05) and lower hospitalization rates (p = 0.025). Prolonged symptom duration was associated with older age (OR: 1.07 [1.04–1.11]; p < 0.001) and systemic lupus erythematosus (OR: 1.47 [1.01–2.12]; p = 0.046). Conclusions: Pediatric patients with rheumatic diseases exhibited a wide range of clinical symptoms after COVID-19 infection. The infection generally did not lead to severe outcomes in this study. COVID-19 vaccination was associated with reduced hospitalization risk and expediting the time to negativity for virus. Impacts: This manuscript demonstrates a comprehensive analysis of the clinical characteristics and outcomes of COVID-19 infection in pediatric patients with rheumatic diseases in China. It provides critical insights into the specific challenges faced by this vulnerable population and offers practical recommendations for improving patient management during periods of increased infectious risk.


  • A single-cell atlas of immunocytes in the spleen of a mouse model of Wiskott-Aldrich syndrome

    by Fangfang Liang, Cheng Peng, Xianze Luo, Linlin Wang, Yanyan Huang, Le Yin, Luming Yue, Jun Yang, Xiaodong Zhao


  • Open Access

    Elevated serum IFN-γand IFN-γ/IL-6 ratio in Kikuchi-Fujimoto disease

    by Tingyan He, Zixuan Shen, Jiayun Ling, Xiaona Zhu, Jun Yang

    Background: Kikuchi-Fujimoto disease (KFD) is typically a benign, self-limiting inflammatory disease. The diagnosis of KFD can be challenging for nonspecific symptoms, laboratory or imaging findings. In this study, we aimed to describe the clinical manifestations of patients with KFD and to access the potential role of serum cytokines in the diagnosis of this disease. Methods: Patients with KFD were retrospectively enrolled from January 2015 to November 2021 at Shenzhen Children’s Hospital. Clinical data were collected from inpatient or outpatient medical records. Serum cytokines were detected by the Flowcytomix technique. Serum levels of cytokines were compared between patients with KFD and SJIA, or patients with KFD and KD. The data of patients without MAS were further analyzed. A receiver operating characteristic (ROC) curve analysis was further performed to access the potential role of serum cytokines in the diagnosis of KFD. Results: Serum cytokines were detected in 25 (43.8%, 25/57) patients with a histological diagnosis of KFD. Compared to SJIA or KD patients, the KFD group had a significantly higher IFN-γ/IL-6 ratio and much lower levels of serum IL-6. The median level of serum IFN-γ in KFD was 41.65 pg/ml (range, 21.04–70.74 pg/ml), which was much higher than that in SJIA (median: 3.33 pg/ml, p = 0.16) or KD (median: 2.6 pg/ml, p = 0.01). After excluding patients with MAS, there was statistical significance in all comparisons of serum IFN-γ, IFN-γ/IL-6 ratio, and serum IL-6. The cutoff values of serum IFN-γ, IL-6, and IFN-γ/IL-6 ratio for differentiating KFD from SJIA were > 8.48 pg/ml, < 47.42 pg/ml, and > 0.45, respectively. The cutoff values of serum IFN-γ, IL-6, and IFN-γ/IL-6 ratio for differentiating KFD from KD were > 8.56 pg/ml, < 50.45 pg/ml, and > 0.45, respectively. The specificity of all those cutoff values for differentiating KFD from SJIA or KD was ≥ 94.7%. Conclusions: For patients with fever of unknown etiology and lymphadenopathy, after excluding HLH or MAS, serum IFN-γ > 8.56 pg/mL and IFN-γ/IL-6 ratio > 0.45 may highly suggest the diagnosis of KFD; serum IL-6 > 50.45 pg/mL indicates that the probability of KFD may be small, and sJIA, KD, and acute infection should be excluded first.


  • Open Access

    JAK inhibitors in systemic juvenile idiopathic arthritis

    by Tingyan He, Yu Xia, Ying Luo, Jun Yang

    Objective: Systemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines. The use of JAKi in SJIA or macrophage activation syndrome (MAS) has only been described in a limited number of case reports. In this study, we aimed to assess the efficacy and potential adverse effects of JAKi in SJIA patients.Methods: Patients with SJIA who received JAKi and underwent at least one assessment of efficacy and safety after JAKi initiation were eligible for this study. Data were collected retrospectively from inpatient or outpatient medical records at JAKi initiation, at 1, 3, 6, 9, and 12 months, after disease flare, after JAKi discontinuation, or at the last follow-up.Results: Ten patients with SJIA were included in the study. At the start of JAKi treatment, all patients presented with active disease; five showed variable adverse effects secondary to glucocorticoids. Seven patients received tofacitinib (one later switched to ruxolitinib). Of these, only two patients showed a complete response of persistent arthritis associated with tocilizumab; tofacitinib was used without a biological DMARD only in two patients, together with MTX, showing a partial response; three patients were nonresponders. Four patients with SJIA-related MAS or persistent hyperferritinemia were treated with ruxolitinib. Ruxolitinib allowed a good response on MAS parameters in three of them. All these four patients required an adjunction or switch to canakinumab later. The median decrease in the daily glucocorticoid dose between JAKi initiation and the last follow-up was 90.6% in patients with complete remission and 77.4% in other patients. Three patients discontinued glucocorticoid treatment after the introduction of JAKi. Severe adverse events, notably serious infection or thrombosis, were not observed during JAKi treatment.Conclusion: JAKi may be an alternative or adjuvant agent for SJIA patients, especially in those with persistently active disease, glucocorticoid-related adverse reactions, or SJIA-MAS.